Introduction
============

Neuroendocrine tumours (NETs) include a wide variety of malignancies, all of which are characterised by cells with a neuroendocrine phenotype. These cells belong to the neuroendocrine system, a combination of nerve elements, such as cells of the chromaffin, non-chromaffin and sympathetic ganglia and paraganglia, and epithelial cells such as the endocrine cells of the gut.

Neuroendocrine cells can be found in various organs or tissues, and so NETs can arise in many different ways. The term carcinoids is often used as a synonym for NETs: it was introduced by Oberndorfer \[[@b1]\] in 1907 to indicate malignant tumours arising in the small intestine and leading to metastases, but characterised by a slow growth not found in other malignancies. However, we now know that carcinoids can have a wide range of malignant subtypes, from very slow-growing midgut carcinoids to very aggressive bronchial carcinoids \[[@b2]\].

According to the recent WHO classification \[[@b3]\], NETs should be stratified into well-differentiated NETs and poorly-differentiated (small-cell) neuroendocrine carcinomas. The former include tumours with a 'benign' or 'uncertain clinical' behaviour that are not usually metastatic, whereas the tumours that form metastases are called neuroendocrine carcinomas because their clinical behaviour is generally aggressive and they have a poor prognosis.

NETs are very rare (fewer than two cases per 100000). Gastroenteropancreatic (GEP) neuroendocrine carcinomas are the most common, and include (foregut, midgut, hindgut) gastrointestinal carcinoids and pancreatic endocrine tumours (PETs). The most frequent of these two categories are respectively midgut carcinoids and gastrinomas.

NETs can be *secreting* or *non-secreting* depending on whether they produce a substance or not, and *functioning* or *non-functioning* on the basis of the specific symptoms related to one or more of the substances produced by the tumour. The most classical symptoms are in carcinoid syndrome, which is almost always linked to liver metastases arising from a carcinoid, with flushing and diarrhoea being the most common. In other cases, a specific syndrome can be found, such as hyperglycaemia in gastrinoma or hypoglycaemia in insulinoma. The clinical picture of a NET may be due to hormonal or hormone-related symptoms/syndromes and/or tumoral expansion. Figure 162 y.o. female with highly proliferative SSTRs positive mediastinal NET. (She received chemotherapy and radiolabelled octreotide sequentially.) (a) Images before treatment. $\documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts,amssymb,amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n}{<-> linotext}{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document} $^{\boldsymbol {111}}$ \end{document}$ In octreotide scans (upper) show uptake in mediastinum. CT images (lower) show a mass in mediastinum. (b) Images after treatment. $\documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts,amssymb,amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n}{<-> linotext}{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document} $^{\boldsymbol {111}}$ \end{document}$ In octreotide scans (upper) does not show uptake in mediastinum. CT images (lower) show a complete response. Figure 268 y.o. male with liver metastases from unknown primary SSTRs negative highly proliferative NET.

Methods
=======

In our patients, the diagnosis of NET is made in three different situations: (1) the patient already has a histological diagnosis of NET when he/she comes to our attention; (2) the patient comes to us without any diagnosis and the diagnosis of NET is made in our institute; and (3) the patient has a diagnosis of a tumour other than NET, and the pathologist's second opinion or a new histological examination changes the diagnosis to NET. In any case, we prefer to perform an internal histological examination in order to ensure a uniform approach.

We have a weekly NET multidisciplinary first outpatient visit service, and a weekly multidisciplinary meeting. However, not all of the patients come directly to this service as some request a specific consultation: if this occurs, any specialist takes the case of the examined patient for the weekly multidisciplinary discussion.

When we discuss the case of a patient with a histological diagnosis of NET, we first decide to treat any symptoms. Somatostatin analogues are very effective in controlling systemic symptoms \[[@b4]\], whereas analgesic drugs or sometimes surgery are required for local symptom control. Figure 364 y.o. male with slowly proliferative SSTRs positive liver metastases from unknown primary NET. He received SST analog $\documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts,amssymb,amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n}{<-> linotext}{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document} $\boldsymbol {+}$ \end{document}$ IFN, chemotherapy, and radiolabelled octreotide sequentially.

After symptomatic therapy, we stage the disease, usually by means of somatostatin receptor scintigraphy (SRS) and helical computed tomography (hCT) or magnetic resonance imaging (MRI) or ultrasound (US). ^111^In-DTPA,D-Phe1-octreotide scintigraphy or OctreoScan ^®^, with single photon emission computed tomography (SPECT), is sensitive and specific in identifying tumours expressing somatostatin 2 and 5 receptors (SSTR-2 and SSTR-5) \[[@b5]\].

In the case of localised disease, radical surgery is the treatment of choice whenever possible because it is the only really curative therapy. However, unlike other carcinomas, these tumours may be indicated for palliative surgery in order to improve symptoms or debulk the disease (even though the latter is still debated) \[[@b6]\].

When defining tumour 'aggressiveness', we consider biological characteristics, such as the proliferation index \[[@b7]\], grading, etc., and an instrumental reassessment whenever possible. This last point is very important, because the biological picture of the tumour is not always directly related to its growth.

If the tumour is 'rapidly-growing', we recommend chemotherapy. As the clinical behaviour of an aggressive NET can be similar to that of a small-cell lung cancer (SCLC), the treatment is the same. Most institutions use cisplatin and etoposide, which lead to a 40--60% response rate but limited survival \[[@b8]\]. In order to avoid neuro- and nephrotoxicity, we are studying a combination of carboplatin and etoposide. About 20 patients have been treated so far, and the regimen has been found to be tolerable and to have a promising response rate.

Chemotherapy is often proposed in the case of a tumour of pancreatic origin, because there have been some interesting reports concerning particularly streptozotocin-based regimens \[[@b9]\]. In histologically or clinically aggressive metastatic pancreatic endocrine carcinomas, we are studying the toxicity and activity of a combination of epirubicin, cisplatin and 5-fluorouracil (5-FU) as a continuous infusion (ECF). About 15 patients have been treated so far, and the preliminary data have prompted us to continue.

In slow-growing NETs with a high density of SSTR-2 and SSTR-5, we are studying the feasibility and efficacy of a multimodal strategy that includes debulking by means of hepatic chemoembolisation and/or surgery for primary tumours and even metastases, combined with systemic treatment with a somatostatin analogue and interferon, and followed by targeted radiotherapy with ^90^Y-DOTATOC \[[@b10]\] or ^177^Lu-DOTATATE. About 40 patients have been treated in this way, 15 of whom received a combination of surgery, chemoembolisation, ^90^Y-DOTATOC and hormonal therapy in various sequences.

Conclusion
==========

NETs are biologically highly heterogeneous and often have a bizarre clinical behaviour. These characteristics, in addition to the rarity of the disease, have led to the development of very different diagnostic and therapeutic approaches.

The large number of specialists who could treat a patient with NET remains a theoretical advantage if the patient is not jointly managed.

In order to increase our knowledge of the disease and offer patients more diagnostic and therapeutic options, we think they should be treated in a multidisciplinary manner, with each being discussed in a multidisciplinary meeting with the aim of establishing a diagnosis-treatment strategy, and patient rather than disease management.

Two cases of aggressive neuroendocrine carcinoma are reported in [Figs. 1 and 2](#F1 F2){ref-type="fig"}. We started with chemotherapy in both cases, because of high risk of early complications (mediastinal syndrome in the first and liver failure in the second case). It was possible to add radiometabolic therapy only in the first case, given the positivity of somatostatin receptors. The second patient received IFN. Both patients are alive and have had long survival so far if we consider the median overall survival for similar conditions. We report a totally different situation in [Fig. 3](#F3){ref-type="fig"}. The low proliferation index and positivity of SSTRs prompted us to prefer SST-analog therapy. This kind of therapy produced long term disease maintenance and concurrent good quality of life unlike chemotherapy.

By effective targeting of human somatostatin receptor subtypes with radiolabeled somatostatin analogues, nuclear medicine techniques play a major role both in the detection and treatment of neuroendocrine tumors \[[@b1b]\].

^111^In-DTPA-Octreotide, also known as ^111^In-Pentetreotide and commercially available as *Octreoscan*, has been the most widely used radiolabeled somatostatin analogue and has proved to be a valuable diagnostic tool with a significant impact on the management of patients with neuroendocrine tumors \[[@b2b]\].

As a result, Octreotide scintigraphy is currently regarded as the first imaging procedure to be performed when there is a clinical and/or laboratory suspicion of a neuroendocrine neoplasm \[[@b3b]\]. The results of *Octreoscan* can direct further diagnostic procedures and ultimately affect patient management \[[@b3b]\].

Both localized and advanced disease as shown by *Octreoscan* are to be confirmed by conventional imaging procedures such as computed tomography (CT) and/or magnetic resonance imaging (MRI) to provide an anatomic substrate to the receptor finding. This appears to be fundamental not only for accurate surgical planning of a primary tumor but also for monitoring treatment in case of metastatic or recurrent disease ([Fig. 1](#F1b){ref-type="fig"}).

Further improvements in the diagnostic accuracy of Octreotide scintigraphy may be expected from new radiochemistry. Successful labeling of advances in Octreotide with Technetium-99m (^99m^Tc) has been recently reported and will likely improve its diagnostic performance due to the more favorable physical characteristics of the radiolabel \[[@b4b]\].

However, new somatostatin analogues such as Lanreotide, Vapreotide and Octreotate have been developed and appear to exhibit higher affinity and a wider spectrum of reactivity with human somatostatin receptor subtypes compared to Octreotide \[[@b1b]\]. Figure 1Sagittal (a) and axial (b) single photon emission computed tomography (SPECT) acquisitions of the thorax performed at 4 h after i.v. injection of 175 MBq of ^**111**^In-Pentetreotide in a male patient who had previously undergone a lingulectomy for a bronchial carcinoid. Focal uptake of the radiotracer can be appreciated along the midline in the mediastinum where a subcarinal enlarged lymph node (arrow) is depicted by contrast-enhanced helical-CT (c).

The role of positron emission tomography (PET) with fluorine-18-labeled fluorodeoxyglucose (^18^F-FDG) in the management of patients with neuroendocrine tumors has long been questioned. However, with the use of the radioligand ^18^F-dopamine (^18^F-DOPA) PET imaging has proved more accurate than both ^18^F-FDG-PET and Octreotide scintigraphy in the detection and staging of neuroendocrine tumors of the gastroenteropancreatic district \[[@b5b]\].

In addition, several positron emitters such as ^64^Cu, ^68^Ga, ^110m^In and ^86^Y have also been successfully coupled to Octreotide \[[@b6b]--[@b9b]\].

The improved spatial resolution of PET will likely result in higher detection rates optimizing the diagnostic accuracy of receptor-mediated imaging \[[@b6b]--[@b8b]\]. Furthermore, the use of the PET technique will enable quantitative evaluation of the radiotracer uptake in both the target as well as the critical organs allowing accurate dosimetric estimates in those patients who are candidates for peptide receptor radionuclide therapy which has become a well-established treatment option in patients with neuroendocrine tumors \[[@b9b]\].

Peptide receptor radionuclide therapy is most commonly performed using the pure β-emitter ^90^Y (*E*~max~=2.27 MeV) coupled to Tyr3-octreotide (TOC) via the macrocyclic ligand tetraazacyclododecane tetraacetic acid (DOTA) \[[@b10b]\]. Treatment with ^90^Y-DOTA-TOC has proved to be safe and effective in patients with advanced neuroendocrine tumors in phase II clinical trials and is currently under investigation as a therapeutic option in patients with localized but inoperable disease \[[@b10b]\].

Functioning tumours
===================

Functioning tumours are named according to the main hormone produced and usually present with the clinical features of this excessive hormone secretion. These tumours may be either benign or malignant, solitary or multiple, or form part of the multiple endocrine neoplasia (MEN) syndrome. The diagnosis is almost always made biochemically and the role of imaging is to localise the tumour prior to surgery and to look for evidence of malignancy.

Insulinomas
-----------

Insulinomas are the most frequent functioning pancreatic tumours accounting for 60% of all islet cell tumours \[[@b1c]\]. They cause spontaneous hypoglycaemia, relieved by glucose, and are associated with high levels of plasma insulin and C peptide levels. Insulinomas are malignant in 10%, multiple in 10% and 4% are associated with MEN type I. The tumours are usually very small: 90% are less than 2 cm and 50% less than 1.3 cm in diameter \[[@b2c]\]. When multiple, the individual lesions are usually even smaller (mean diameter 9 vs. 13 mm) \[[@b3c]\]. Patients with MEN type I usually have multiple small tumours. Malignant insulinomas tend to be larger than benign ones (2.5--12 cm in diameter) \[[@b2c]\].

Gastrinomas
-----------

Gastrinomas are the second most common functioning islet cell tumours of the pancreas accounting for 18% of all islet cell tumours \[[@b1c]\]. They give rise to the Zollinger--Ellison syndrome, which comprises increased gastric acid secretion, diarrhoea and peptic ulceration. The diagnosis is established by the demonstration of a raised fasting serum gastrin level with high basal gastric acid output. Over 90% of gastrinomas are found in the 'gastrinoma triangle' bounded by the third part of the duodenum, the neck of the pancreas and the porta hepatis \[[@b4c]\]. Gastrinomas are multiple in 20--40% of patients and often extra-pancreatic, with 20% found in the duodenum. Gastrinomas are frequently malignant with metastatic spread occurring to the liver and local lymph nodes. They tend to be small: 38% of pancreatic and all duodenal tumours are less than 1 cm in diameter at diagnosis. One-third of cases are associated with MEN type I in which multiplicity is the rule and there is a tendency to recurrence.

Glucagonomas
------------

Glucagonomas cause non-ketogenic diabetes mellitus and a characteristic migrating, necrolytic rash, as well as stomatitis, diarrhoea and venous thrombosis. The tumours have an average diameter of 4--7 cm at diagnosis and are malignant in approximately 60% of cases.

VIPomas
-------

VIPomas produce watery diarrhoea, hypokalaemia and achlorhydria (Verner--Morrison syndrome). The tumours range in diameter from 2 to 7 cm at diagnosis. The site of the tumour is intrapancreatic in 90% of cases, with the remainder (mainly gangliomas or ganglioneuroblastomas) originating in the sympathetic chain or adrenal medulla. Most extrapancreatic tumours are benign, but 50% of pancreatic VIPomas are malignant.

Somatostatinomas
----------------

Somatostatinomas are very rare, slow-growing tumours, which produce the clinical triad of gallstones, diabetes mellitus and steatorrhoea. These tumours arise from the pancreas in 50% and the duodenum in 50% of cases. Duodenal somatostatinomas occur in association with neurofibromatosis and are usually periampullary in position.

Pancreatic polypeptide
----------------------

Pancreatic polypeptide is often secreted in association with other hormones. Isolated secretion is very rare and does not produce a recognised clinical syndrome.

Non-functioning tumours
=======================

Non-functioning tumours account for 15% of pancreatic neuroendocrine tumours \[[@b1c]\]. They do not usually present until the tumour is large enough to cause symptoms from mass effect. The tumours tend to be large, solid and malignant, but are usually slow growing.

Imaging islet cell tumours
==========================

Transabdominal ultrasound
-------------------------

Transabdominal ultrasound is generally the first-line investigation. On ultrasound (US), islet cell tumours are usually seen as a well-circumscribed mass of lower echogenicity and finer echotexture than the normal pancreatic parenchyma. There may be a hyperechoic rim and larger tumours may show evidence of necrosis or calcification. A few lesions, especially gastrinomas, may be hyperechoic. Some lesions are isoechoic and are seen due to a hypoechoic halo around the lesion or due to the distortion of the gland. In malignant tumours, liver metastases are mostly hyperechoic or heterogeneous \[[@b2c]\]. Larger lesions may show evidence of cystic degeneration. The overall detection rate for insulinomas is about 25--63%, but is up to 70% if the pancreas is adequately visualised. The reported detection rate for gastrinomas is lower with only 30% identified \[[@b5c]\]. The sensitivity is better for intrapancreatic gastrinomas than extrapancreatic lesions. The relatively low sensitivity of transabdominal US is mainly due to overlying bowel gas.

Endoscopic ultrasound (EUS)
---------------------------

Endoscopic ultrasound (EUS) allows high-frequency probes (7.5--12 MHz) to be placed in close proximity to the pancreas and duodenum. In experienced hands, it has proved sensitive in detecting tumours of the pancreatic head but has been less successful for lesions of the pancreatic tail and duodenum. It is also possible to detect gastrinoma located in the bowel wall. Sensitivities as high as 79--100% have been reported \[[@b6c]--[@b9c]\]. EUS is superior to transabdominal US \[[@b10c]\]. The procedure is expensive and invasive and the equipment and expertise are not widely available. Its eventual role remains to be defined.

Intraoperative ultrasound
-------------------------

Intraoperative ultrasound provides high-resolution images with 7.5--10 MHz probes. Like EUS, it is highly operator-dependent, but in experienced hands it is extremely effective for the identification of insulinomas at surgery. It is much less effective, however, for the identification of gastrinomas, since it is unable to identify extrapancreatic tumours of this type \[[@b11c], [@b12c]\]. Intraoperative US does not replace preoperative localisation of islet cell tumour in most institutions but is used as an adjunct to palpation.

Computed tomography (CT)
------------------------

Computed tomography (CT) is the most widely used method for localising islet cell tumours. Most islet cell tumours are isodense on unenhanced CT and will not be seen without intravenous (IV) administration of contrast medium unless they are large enough to deform the pancreatic outline. Occasionally small tumours may be apparent as a hypodense mass. Calcification may occur in up to 20% of cases and is more common in malignant than benign tumours \[[@b13c]--[@b15c]\]. Larger lesions may show central necrosis and are also more likely to calcify. On contrast-enhanced CT, islet cell tumours are generally seen as a rounded area that enhances more than the surrounding pancreas, although hypodense lesions do occur \[[@b16c]\].

With spiral CT it is now possible to perform two-phase data acquisition of the pancreas in both the arterial and parenchymal phases following IV contrast enhancement \[[@b17c]\]. This has improved the sensitivity of CT for the detection of small islet cell tumours \[[@b17c], [@b18c]\]. Primary islet cell tumour and metastases are usually better seen on the arterial phase than the delayed phase \[[@b19c]\]. The reported sensitivity of CT in detecting primary islet cell tumours is 44--80% depending on the size of the tumour \[[@b2c]\].

Hepatic metastases are generally highly vascular and are seen as low attenuation areas on unenhanced CT. Central necrosis is common in larger lesions and calcification may occur. Following IV contrast the lesions are enhanced. A solitary lesion may be indistinguishable from a haemangioma.

Magnetic resonance imaging (MRI)
--------------------------------

Magnetic resonance imaging (MRI) is increasingly being used in the localisation of islet cell tumours. The advent of fast spin-echo, fat saturation and dynamic contrast-enhanced imaging has resulted in greatly improved imaging for pancreatic lesions \[[@b20c]\]. Studies comparing MRI and CT have shown that MRI has greater sensitivity than CT, particularly for smaller islet cell tumours \[[@b21c]\]. In general, islet cell tumours are of lower signal intensity on T1-weighted images and of higher signal intensity on T2-weighted images than normal pancreas \[[@b22c], [@b23c]\]. As on CT, the lesions tend to be enhanced following IV administration of contrast agent such as gadolinium \[[@b21c]\].

Arteriography
-------------

Arteriography remains an important tool in localising neuroendocrine tumours. As with other imaging investigations, attention to the details of the technique is required for the best results. Unless superselective studies are performed the tumour may be missed \[[@b24c]\] so selective arteriography of the superior mesenteric artery, the splenic artery, the gastroduodenal artery, the dorsal pancreatic artery, common hepatic artery and any accessory hepatic arteries should be included. Hepatic arteriography is performed both to demonstrate the arterial anatomy for the surgeon and to identify any liver metastases.

Islet cell tumours typically appear as a well-circumscribed blush in the capillary and early venous phase. Abnormal feeding vessels may be seen in large tumours. Angiographic features of malignant lesions include tumour irregularity, marked tortuosity of the feeding vessels, arterial encasement and venous obstruction \[[@b25c]\].

The reported sensitivity of selective angiography for insulinoma is between 54 and 89% and for gastrinomas between 64 and 100% \[[@b2c]\]. In patients with multiple tumours the sensitivity for individual lesions is lower. Lesions may be missed on angiography because they are too small or hypovascular or are obscured by the blush of adjacent bowel or spleen. False-positives result from misinterpretation of blush of adjacent bowel, splenunculus, or angiomas.

Venous sampling
---------------

Venous sampling allows functional radiological localisation of insulinomas and gastrinomas.

### Transhepatic portal venous sampling (TPVS)

Transhepatic portal venous sampling (TPVS) is performed by transhepatic catheterisation of the right portal vein with a 5F catheter. Samples for hormonal analysis are obtained from the splenic vein, superior and inferior mesenteric veins, and portal and pancreatic veins. The exact location of the tumour cannot be pinpointed in the same way as in an imaging study and TPVS only localises the tumour to a region of the pancreas. Problems of interpretation may also arise when there are multiple tumours or if the hormone gradient is low. Transhepatic portal catheterisation is an invasive procedure with a significant complication rate and mortality \[[@b26c]\].

### Arterial stimulation and venous sampling (ASVS)

Arterial stimulation and venous sampling (ASVS) involves selective pancreatic arterial injections of a secretagogue (calcium for insulinoma and secretin for gastrinoma) and hepatic venous outflow is sampled. When arteries supplying the tumour are injected there is a rise in the hepatic venous hormone concentration. Lesions not seen on cross-sectional studies can be detected \[[@b27c]\].

The sensitivity of ASVS is comparable to portal venous sampling for localisation of insulinoma and better than portal venous sampling for localisation of gastrinomas \[[@b28c], [@b29c]\]. It can be performed as part of pancreatic angiography and involves none of the risks associated with portal venous sampling, such as hepatic arteriovenous fistulae, haemobilia and superior mesenteric vein occlusion. Despite these possible complications, portal venous sampling may occasionally be useful in patients with suspected insulinomas if all other preoperative studies are negative; properly performed, it is the most sensitive preoperative test for localisation of insulinomas, with a sensitivity of 80--90% \[[@b30c]\].

Scintigraphy
------------

For neuroendocrine tumours of the pancreas and bowel scintigraphy can be performed using radiolabelled somatostatin analogues and vasoactive intestinal peptide (\[^123^I\]VIP). [Table 1](#T1){ref-type="table"} summarises the proportions of tumours that are scan-positive. The radiolabelled somatostatin analogue, \[^111^In\]pentetreotide, is able to image a variety of somatostatin receptor-positive tumours. The main advantages of scintigraphy are its ability to image the whole body and to detect tumours or their metastases as small as 1 cm in diameter, especially in areas not under clinical suspicion. These imaging techniques can also be used to monitor the effects of therapy \[[@b31c]\]. These small tumours can also be located at surgery using hand-held gamma probes. Table 1Proportions of tumours that are scan-positiveType of tumour\[^111^In\]Pentetreotide (%)\[^123^ I\]VIP (%)Gastrinomas80---Glucagonomas95---Carcinoid8685Insulinomas6182Somatostatinomas100---VIPomas80100

Localisation of islet cell tumours
==================================

The localisation of islet cell tumours presents a challenge to the radiologist as several imaging techniques are capable of demonstrating the tumour and no one technique is superior to the others.

A rational approach to the localisation of these tumours requires careful consideration of cost, sensitivities and availability of the imaging techniques. In most cases, initial imaging with a combination of US and CT or MRI will demonstrate the tumour and hepatic metastases. If these tests are negative or equivocal, arteriography (with ASVS) is the next line of investigation. If the tumour remains undetected, further investigation depends on local expertise. EUS is emerging as a highly sensitive test for small pancreatic tumours and may also demonstrate extrapancreatic gastrinomas. Intraoperative US is a useful adjunct to palpation at the time of surgery. Somatostatin receptor imaging is useful in somatostatin receptor-positive tumours not detected by other imaging techniques.

This article was originally published in *Cancer Imaging* (2003) volume 4, issue 1, pp 1--4 with the title 'Islet cell tumours' and is available online at <http://www.cancerimaging.org>. In the event of a change in the URL address, please use the DOI provided to locate the article.

Introduction
============

Carcinoid tumours, together with insulinomas, gastrinomas, non-functioning islet cell tumours, vipomas, glucagonomas and somatostatinomas, are grouped together as neuroendocrine neoplasms that belong to a more general category of tumours called the 'APUDomas' (amine precursor uptake and decarboxylation tumours).

Carcinoids account for 25% of all primary small bowel tumours. Unlike adenocarcinomas, they are 10 times more common in the ileum than in the jejunum and duodenum, rarely arising from Meckel's diverticulum.

With a typically slow growth pattern, carcinoids are asymptomatic in their early development or may present with vague abdominal pain or dyspepsia for 5--7 years. All such tumours can release hormonally active amines or peptides responsible for gastrointestinal (GI), metabolic and/or vasomotor symptoms. The carcinoid syndrome is a late and infrequent presentation always associated with elevation of plasmatic serotonin and urinary 5-hydroxyindole acetic acid (5-HIAA): periodic cutaneous flushing, diarrhoea and bronchospasm may occur. Carcinoid syndrome occurs in 4--10% of cases when vasoactive hormones can enter into systemic circulation. Prolonged survival of patients with carcinoid tumour is not uncommon, with reported survival rates of more than 80% at 5 years, even in the presence of distant metastases \[[@b1d]\]. Treatment should prevent tumour growth and limit biological effects of tumour secretion.

Despite the slow growth, all carcinoids are potentially malignant tumours spread along a unique biological spectrum. The two ends of the scale can be considered the benign and malignant stages of a pathologic process whose biological behaviour cannot be predicted on the basis of histological features, but on the extent of local invasion and the presence of distant metastases instead. In other words, the extent of invasion is a function of size, anatomic location and time: local and distant spread are seen in only 2% of tumours less than 1 cm in diameter but in up to 80% of tumours more than 2 cm in diameter.

Imaging
=======

General considerations in imaging of intestinal carcinoid
---------------------------------------------------------

Despite significant improvements in diagnostic techniques and operative mortality, the survival of patients with primary malignant tumours of the small bowel has changed little since the late 1960s. In effect many patients have advanced tumours at surgery because of a delayed diagnosis \[[@b2d]\]. These delays may derive from a variety of reasons, including failure of physicians to order appropriate diagnostic tests, and failure of radiologists to reach the correct diagnosis. The small bowel is a potential source of unexplained abdominal symptoms and appropriate radiologic tests are needed.

In our opinion the preoperative imaging demonstration of a malignant tumour of the small bowel depends primarily on a barium examination or a computed tomography (CT) technique: the proximal jejunum sometimes is evaluated during upper GI tract endoscopic examinations and the distal part of the terminal ileum is often evaluated during colonoscopy.

The conventional barium studies are relatively inaccurate tests to diagnose a small bowel tumour, particularly a small bowel carcinoid. The reported sensitivity of the small bowel follow-through study varies widely. The abnormalities are present, in various series, in 53--83% of patients with primary small bowel tumour, but direct evidence of tumour is found in only 30--44% of cases \[[@b3d]--[@b5d]\].

Imaging techniques in carcinoid detection
-----------------------------------------

In small bowel tumours evaluation we prefer CT. The use of CT, in effect, is controversial in GI tube study, but new technical and clinical improvements in spiral CT studies have substantially changed the approach in GI tract imaging. The speed acquisition in spiral technology (in single and in multislice devices), the improvements in spatial and temporal resolution in contrast-enhanced CT studies, and the new software to realise multiplanar reformation of images have substantially modified the CT imaging of the GI tract \[[@b6d]\].

The small bowel in GI imaging is a segment of main radiological interest because in this study the endoscopic technique encounters the greatest difficulties. In performing CT examination, on the other hand, some basic conditions are required to obtain an adequate evaluation. The first obstacle in GI tube evaluation is the physiological tendency of bowel loops to collapse. Collapsed loops determine some artefacts in bowel wall evaluation: it is not possible to evaluate intrinsic lesions and the wall enhancement is poorly detectable.

We proposed some years ago the CT enteroclysis technique \[[@b7d]\]. The forced distension of the bowel wall allows good detection of the lesions in inflammatory and tumoral diseases. In order to obtain the loops distension, the use of a nasojejunal tube overcomes any rate of gastric emptying by infusing the endoluminal contrast medium at the desired rating; the transparent endoluminal contrast medium allows a better visualisation of the bowel wall, where any lesions are enhanced by the iodinated intravenous contrast medium.

The distension of the bowel wall highlights the reduced segmental distensibility in case of wall lesions due to ulcers or tumours.

The visualisation of all the intestinal loops in the distended state enables the detection of distortions or kinks in their outline due to adherences.

In our technique the intestinal cleansing before the examination is essential to avoid any mistakes between pathologic wall lesions or endoluminal findings and the residual intestinal contents; some information is necessary with regard to the ascending colon as well as the small intestine during the same examination study. In small bowel study the colon preparation is needed: a non-absorbable iso-osmolar solution-based preparation is used 6--7 h before the examination. As well as being well tolerated by the patient, this preparation has no irritant effect on the mucosa of the small intestine and the colon, which could give rise to confusion or diagnostic difficulty. Intestinal preparation is not performed in patients with intestinal obstruction, who are examined only in basal conditions without any enteroclysis.

CT findings
===========

Considering the GI tract segments potentially involved by carcinoids, only a few cases of tumour of the oesophagus have been reported. Carcinoid of the oesophagus and stomach account for fewer then 5% of GI carcinoid tumours \[[@b8d]\]. The tumour arising from the basal part of the mucosa has a polypoid appearance.

The frequency of duodenal carcinoids is similar to that of gastric carcinoids. They are located mostly in the first and second portions of the duodenum. They may be associated with multiple endocrine neoplasia, Zollinger--Ellison syndrome, or neurofibromatosis. They are usually low-grade malignant tumours that appear as small polyps. Endoscopy is the best technique for diagnosis because biopsy is allowed.

The small bowel is the second most frequent site of carcinoid tumours after the appendix, representing up to 20% of GI carcinoids. Ileal and jejunal carcinoids are usually aggressive because of their hidden location.

Polypoid or mural smoothly marginated subtle masses within a bowel wall thickening are described in CT imaging literature \[[@b9d], [@b10d]\]. In some cases dilated small bowel loops are detectable ([Fig. 1](#F1d){ref-type="fig"}). As the tumour grows it will usually extend in adjacent mesentery ([Fig. 2](#F2d){ref-type="fig"}(a, b)). Figure 1CT enteroclysis with intravenous contrast medium, axial scan: two dilated ileal loops before a carcinoid (head arrow) of the intestinal wall. Figure 2(a) CT enteroclysis with intravenous contrast medium, axial scan: carcinoid lesion (head arrow) in the mesenteric fat. The arrow shows the duodenal tube. (b) The carcinoid (head arrow) lesion is shown: the mesentery is hyperemic (arrows).

At this point the CT appearance is fairly characteristic. On CT the mesenteric extension from carcinoid will usually appear as a soft tissue density mesenteric mass ([Fig. 3](#F3d){ref-type="fig"}(a, b)). The mesenteric mass often has a spiculated appearance due to desmoplastic reaction ([Fig. 4](#F4d){ref-type="fig"}). Figure 3(a, b) CT enteroclysis with intravenous contrast medium, axial scan: in these two cases the carcinoid lesion appears as a mesenteric mass (arrows). Figure 4CT enteroclysis with intravenous contrast medium, axial scan: the carcinoid (asterisk) is a mesenteric mass, with the typical arterious enhancement. The desmoplastic reaction is detectable in the mesenteric fat, around the lesion.

In effect the local action of serotonin which the tumour locally produces provokes an intense desmoplastic effect; this fibrotic reaction often produces fixation and kinking of bowel loops, sometimes leading to obstruction. This desmoplastic change can also involve blood vessels in the mesentery and this will occasionally cause ischaemia in the affected bowel loops.

As the carcinoid lets out mesenteric metastases, more specific radiographic features can be detected: crowding of folds at the edge of the mass, kinking of the bowel wall, narrowing of the lumen and even annular changes may occur ([Fig. 5](#F5d){ref-type="fig"}). On CT, a stellate density with strands of fibrosis radiating towards the adjacent bowel loops represents a peritoneal metastasis that has become larger than the primary tumour. The finding of desmoplastic streaks resembling the 'sun's rays' is pathognomonic of carcinoid tumours \[[@b8d]\] ([Fig. 6](#F6d){ref-type="fig"}). Figure 5(a) CT enteroclysis with intravenous contrast medium, axial scan: the carcinoid lesion is undetectable on CT scans. The lesion induce an important desmoplastic reaction (arrows) in the mesentery and it causes the intestinal occlusion with ileal loops distension (arrow heads). (b) Intra-operative image of the same case: the asterisk shows the carcinoid, on the right (arrow head) the dilated loop, on the left the post-stenotic ileal tract. Figure 6CT enteroclysis with intravenous contrast medium, axial scan: the carcinoid (arrow) induce an intense desmoplastic reaction. The ileal loops are well distended with methilcellulose. No signs of bowel wall ischemia are detectable. Mucosal folds (arrow heads) of ileal loops are well demonstrated.

Small carcinoids may be mucosal or submucosal in appearance, without desmoplastic changes, and the differentials include leiomyomas, adenomas, lipomas and hamartomas ([Fig. 7](#F7d){ref-type="fig"}). Occasionally however, the interpretation of mesenteric retraction can be problematic. Sclerosing mesenteritis, Hodgkin's disease, radiation damage and extensive metastatic diseases can share the same appearance on conventional CT images \[[@b11d]\]. Figure 7CT enteroclysis with intravenous contrast medium, axial scan: a small carcinoid (arrow) of an intestinal ileal loop is mucosal, without any evident desmoplastic reaction: the differentials diagnosis was made with a leiomyoma.

The lesion can appear isodense when compared with the adjacent hepatic parenchyma during the portal phase. In this regard, the spiral CT technique has improved the detectability of hepatic metastases, particularly in small lesions.

Discussion
==========

Carcinoids account for 25% of all primary small bowel tumours; the most common small bowel malignancy is still a secondary malignancy from either colorectal or gynaecological origin, followed by primary lymphomas and adenocarcinomas \[[@b14d], [@b15d]\].

The sensitivity of small bowel barium examinations in the detection of early neuroendocrine neoplasms depends on the stage of the disease and on the technique used. On the other hand, the malignant potential of carcinoids is not a deterministic feature, but typically varies for a single tumour as a function of time and size. Hence, early detection is of key importance as early carcinoids have usually not yet involved mesenteric lymph nodes so their resection can be radically curative. This is why, although the radiographic finding of a round, small mass elevating the mucosa lacks specificity, the hypothesis of a carcinoid has to be at the top of the differential diagnostic list.

In the case of multiple carcinoids, the presence of at least one advanced lesion should be suspected and a CT examination should be performed to demonstrate mesenteric metastases. The lesion is expected to be multiple in some 30% of cases and may be associated with other tumours. Similarly, there is considerable suspicion of malignant progression within the tumour when it exceeds 2 cm in diameter.

CT study is a complete method to detect suspected endocrine tumours of the bowel. The tomographic technique extends the evaluation to the whole abdominal cavity, evaluating the main lesions and all possible distant metastases, while the enteroclysis technique allows the complete evaluation of the bowel wall.

CT may fail to reveal the primary tumour. Since virtually all carcinoids contain somatostatin receptors at cell interfaces, receptor scanning with somatostatin analogues (octreoscan) and meta-iodobenzylguanidine (MIBG) radionuclides can make the difference in detecting small active primaries \[[@b12d], [@b13d]\].

Hepatic and peritoneal metastases
---------------------------------

Staging hepatic disease is mandatory in cases with carcinoid tumour. On CT, hepatic and peritoneal metastases can have different features and because of their hypervascular nature, they are better depicted during the arterial phase of the bolus ([Fig. 8](#F8d){ref-type="fig"}). Figure 8(a, b): Spiral CT enteroclysis with intravenous contrast medium, axial scan: two cases of hepatic metastases. The secondary lesions are typically hyperaemic (arrows).

Hepatic involvement can be assessed non-invasively with ultrasound, CT or magnetic resonance imaging. Typical neuroendocrine metastases are hypervascular and show early enhancement after administration of i.v. iodine contrast or paramagnetic substance. A regular peripheral rim of contrast enhancement with poor to moderate accumulation within the tumour resembles the typical appearance \[[@b16d]\].

Isotope scanning/positron emission tomography are alternative sensitive and specific modalities in detecting liver metastases. They can also be of help in predicting which patients will benefit from lantreotide therapy, a medication effective in relieving flushing and diarrhoea in patients with tumours expressing somatostatin receptors (80--85%). In patients with an advanced disease, all imaging techniques change the therapeutic management to a comparable extent. Hence, a combined imaging approach should be suggested \[[@b17d]\].

Conclusion
==========

According to the neuroendocrine concept, all the neoplasms capable of anabolic activity from amine precursors are considered as whole apudomas. This spectrum includes fully benign lesions, frankly invasive tumours and a continuum of lesions with increasing malignant potential between the two ends of the scale. Not all histotypes can be biologically specialised to the extent that they succeed in the secretion of any specific hormonal substance. If they do, the patient can experience GI, metabolic and/or vasomotor symptoms from the relative amine or peptide.

In small bowel, carcinoid tumours are amongst the most common apudomas together with insulinomas, gastrinomas, non-functioning islet cell tumours, vipomas, glucagonomas and somatostatinomas. The biological behaviour of a specific tumour can be predicted on the basis of its size and is susceptible to changes with malignant progression as time passes.

Liver metastases and the development of the related carcinoid syndrome do not represent a major threat for patients with a neuroendocrine tumour of the small bowel. The spread of the disease within the peritoneal cavity with ischaemic and obstructive complications usually occurs prior to hepatic involvement and significantly affects the patient's outcome. Due to the often aspecific presentation with vague pain, nausea, weight loss and the extremely small size of these neoplasms, neuroendocrine tumours of the small bowel continue to pose a significant diagnostic challenge in their very early stage. Spiral CT and the CT enteroclysis technique allow a complete staging of the carcinoid tumours. CT demonstrates all details about the site of the primary tumour, and it evaluates the bowel wall involvement demonstrating the extraintestinal extension of the disease. CT performs a precise evaluation of nodal and peritoneal disease and of hepatic involvement to obtain a systemic staging of the disease.
